IRB #

IRB00011025

Title

Addition of Pembrolizumab Upon Progression on Enzalutamide in men with mCRPC

Principal Investigator

Julie Graff

Study Purpose

The purpose of this study is to test how a new immunotherapy drug called pembrolizumab affects cancer cells through measuring prostate specific antigen (PSA), imaging studies, and tissue and blood samples. The research will involve molecular, cellular, and immunologic (immune system) experiments that use blood and tumor specimens. Investigators hope that the information gained from these studies will lead to a greater understanding of immune therapy for prostate cancer and potentially, improvements in prostate cancer treatment.

Medical Condition(s)

Metastatic Castrate Resistant Prostate Cancer

Eligibility Criteria

-Prostate cancer that has spread outside the prostate and no longer responds to hormone therapy
-current use of enzalutamide, with cancer progressing despite this treatment
-no prior immunotherapy

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

12 weeks to 48 weeks

Minors Included

No

Contact

OHSU Knight Cancer Institute Information Line
Email: trials@ohsu.edu
Call: 503-494-1080

Sponsor

OHSU Knight Cancer Institute, supported by Merck Sharp & Dohme Corp.

Recruitment End

12/31/2022

Compensation Provided

No


Go Back